gadofosveset trisodium (ablavar) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Gadofosveset is a gadolinium-based MRI contrast agent. It was used as the trisodium salt monohydrate form. It acts as a blood pool agent by binding to human serum albumin. The manufacturer discontinued production in 2017 due to poor sales.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

ablavar | gadofosveset | gadofosveset trisodium | gadofoveset | ms 325 | ms-325 | ms-32520 | vasovist

Organizations (11)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Diagnostic Imaging (approved 2008)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Arterial Occlusive Diseases (Phase 3)

Atherosclerosis (Phase 1)

Heart Defects, Congenital (Phase 4)

Heart Diseases (Phase 4)

Intermittent Claudication (Phase 1)

Myocardial Ischemia (Phase 2)

Ovarian Neoplasms (Phase 4)

Peripheral Arterial Disease (Phase 1)

Peripheral Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue